Company intelligence / Profile preview
Shenzhen Hemogen Therapeutic Co., Ltd.
Shenzhen, Guangdong Sheng, Chinahemogen.cn ↗
- Ownership
- Private
- Employees
- ~35
- Development stage
- Phase 2
01
Overview
The company's lead product HGI-001 Injection has successfully helped multiple transfusion-dependent β-thalassemia patients achieve transfusion independence in investigator-initiated trials, with the first patient maintaining independence for over 27 months. The product is currently in Phase 2 clinical trials.
- Therapeutic areas
- HematologyImmunologyNeurology
- Modalities
- Gene therapyCRISPR/Cas9Lentivirus vectors
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
CG Therapeutics Private Limited (Malaysia)
Beyond the preview
Go deeper on Shenzhen Hemogen Therapeutic Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shenzhen Hemogen Therapeutic Co., Ltd..